^
Association details:
Biomarker:FLT3-ITD mutation
Cancer:Acute Myelogenous Leukemia
Drug Class:FLT3 inhibitor +
LIMK2 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells

Published date:
12/13/2020
Excerpt:
...we investigated the therapeutic potential of the LIMK1/2 inhibitor CEL_Amide (LIMKi) in FLT3-ITD+ AML....LIMK1/2 inhibition by the small molecule CEL_Amide seems to have promising activity in combination with FLT3 inhibitors in vitro as well as in vivo and may constitute a novel treatment strategy for FLT3-ITD+ AML.
DOI:
10.1016/j.leukres.2020.106490